Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and when can generic versions of MERCK drugs launch?
MERCK has ninety-two approved drugs.
There are twenty-six US patents protecting MERCK drugs.
There are seven hundred and thirty-five patent family members on MERCK drugs in sixty-three countries and one hundred and seventy-eight supplementary protection certificates in nineteen countries.
Summary for Merck
| International Patents: | 735 |
| US Patents: | 26 |
| Tradenames: | 77 |
| Ingredients: | 70 |
| NDAs: | 92 |
| Patent Litigation for Merck: | See patent lawsuits for Merck |
| PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-003 | Jan 19, 2021 | RX | Yes | Yes | 8,420,656 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-004 | Aug 13, 2014 | RX | Yes | Yes | 7,951,797 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-002 | Jan 19, 2021 | RX | Yes | No | 11,439,642 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-002 | Oct 16, 2006 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck | HYDELTRASOL | prednisolone sodium phosphate | INJECTABLE;INJECTION | 011583-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-004 | Sep 18, 2012 | 6,303,661 | ⤷ Try a Trial |
| Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-001 | Dec 29, 1987 | 4,374,829*PED | ⤷ Try a Trial |
| Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 022023-001 | Jan 25, 2008 | 7,214,692 | ⤷ Try a Trial |
| Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-002 | Oct 7, 2011 | 7,459,428 | ⤷ Try a Trial |
| Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-001 | May 20, 1999 | 6,063,811*PED | ⤷ Try a Trial |
| Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-002 | Dec 14, 1990 | 5,147,868 | ⤷ Try a Trial |
| Merck | DOLOBID | diflunisal | TABLET;ORAL | 018445-001 | Apr 19, 1982 | 3,674,870 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
| ➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
| ➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
| ➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
| ➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
| ➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
| ➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
| ➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
| ➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
International Patents for Merck Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2864009 | ⤷ Try a Trial |
| Denmark | 1455756 | ⤷ Try a Trial |
| Lithuania | PA2008007 | ⤷ Try a Trial |
| Denmark | 2782914 | ⤷ Try a Trial |
| Luxembourg | 91910 | ⤷ Try a Trial |
| Japan | 2010539193 | ⤷ Try a Trial |
| Norway | 20042165 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| 1412357 | CA 2008 00035 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID |
| 0734381 | 3/2004 | Austria | ⤷ Try a Trial | PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111 |
| 2666774 | 20C1032 | France | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM OPTIONNELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE OPTIONNELLEMENT SOUS FORME DE SEL SODIQUE; REGISTRATION NO/DATE: EU/1/19/1420 20200217 |
| 1429780 | 13C0012 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 0503785 | 91330 | Luxembourg | ⤷ Try a Trial | CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS) |
| 1412357 | 07C0041 | France | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINE, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET EN PARTICULIER LE PHOSPHATE DE SITAGLIPTINE MONOHYDRATE; REGISTRATION NO/DATE: EU/1/07/383/001 20070323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
